These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1987024)

  • 21. [Studies on post-splenectomy infection and immune activation by muramyl peptide. A new concept in the prevention of severe infections].
    Izbicki JR; Ziegler-Heitbrock HW; Lütticken R; Ruckdeschel G; Wilker DK; Schweiberer L
    Chirurg; 1991 Mar; 62(3):195-200. PubMed ID: 2036895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
    Asano T; Matsushima K; Kleinerman ES
    Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
    Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC
    Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
    Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
    J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens.
    Ullrich SE; Fidler IJ
    J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
    Meyers PA; Chou AJ
    Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
    Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
    Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide.
    Saiki I; Milas L; Hunter N; Fidler IJ
    Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity.
    Kurzman ID; Cheng H; MacEwen EG
    Cancer Biother; 1994; 9(2):113-21. PubMed ID: 7529085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
    Kurzman ID; MacEwen EG; Rosenthal RC; Fox LE; Keller ET; Helfand SC; Vail DM; Dubielzig RR; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Dec; 1(12):1595-601. PubMed ID: 9815961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.
    Hisano G; Fidler IJ
    Cancer Immunol Immunother; 1982; 14(2):61-6. PubMed ID: 6965228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
    Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
    J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
    Kleinerman ES; Snyder JS; Jaffe N
    J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide.
    Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ
    Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.
    Malik ST; Martin D; Hart I; Balkwill F
    Br J Cancer; 1991 Mar; 63(3):399-403. PubMed ID: 2003980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.